Coming together at the hinges: Therapeutic prospects of IgG3

References

• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–15. doi:10.1182/blood-2008-09-179754.
   PubMed Web of Science ®Google Scholar
• Goh YS, Grant AJ, Restif O, McKinley TJ, Armour KL, Clark MR, et al Human IgG isotypes and activating Fcgamma receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells. Immunology. 2011;133(1):74–83. doi:10.1111/j.1365-2567.2011.03411.x.
   PubMed Web of Science ®Google Scholar
• Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67(2):171–82. doi:10.1016/j.molimm.2015.03.255.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J. 1990;9(Supplement):S16–24. doi:10.1097/00006454-199008001-00004.
   PubMedGoogle Scholar
• Hansen K, Lau AM, Giles K, McDonnell JM, Struwe WB, Sutton BJ, et al. A Mass-Spectrometry-Based Modelling Workflow for Accurate Prediction of IgG Antibody Conformations in the Gas Phase. Angewandte Chemie. 2018;57(52):17194–99. doi:10.1002/anie.201812018.
   Google Scholar
• Ellison J, Hood L Linkage and sequence homology of two human immunoglobulin gamma heavy chain constant region genes. Proceedings of the National Academy of Sciences of the United States of America 1982; 79: 1984–88.
   Google Scholar
• Huck S, Fort P, Crawford DH, Lefranc MP, Lefranc G. Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cγgenes. Nucleic Acids Res. 1986;14(4):1779–89. doi:10.1093/nar/14.4.1779.
   PubMed Web of Science ®Google Scholar
• Broug E, Bland-Ward PA, Powell J, Johnson KS. Fab-arm exchange. Nat Biotechnol. 2010;28(2):123–25. author reply 125-126. doi:10.1038/nbt0210-123.
   PubMed Web of Science ®Google Scholar
• Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol. 1986;63:127–34.
   PubMed Web of Science ®Google Scholar
• Lilie H, Rudolph R, Buchner J. Association of antibody chains at different stages of folding: prolyl isomerization occurs after formation of quaternary structure. J Mol Biol. 1995;248(1):190–201. doi:10.1006/jmbi.1995.0211.
   PubMed Web of Science ®Google Scholar
• Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, et al Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem. 2008;283(23):16194–205. doi:10.1074/jbc.M709987200.
   PubMed Web of Science ®Google Scholar
• Lightle S, Aykent S, Lacher N, Mitaksov V, Wells K, Zobel J, et al. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. Protein Science: A Publication of the Protein Society. 2010;19(4):753–62. doi:10.1002/pro.352.
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, et al. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem. 2008;283(43):29266–72. doi:10.1074/jbc.M804787200.
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell. 2015;27(1):138–48. doi:10.1016/j.ccell.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao Y, Shi H, Zhang Y, Yin X, Liu M, et al. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nat Commun. 2019;10(1):4206. doi:10.1038/s41467-019-12097-6.
   PubMedGoogle Scholar
• Konitzer JD, Sieron A, Wacker A, Enenkel B. Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro. PLoS One. 2015;10(12):e0145633. doi:10.1371/journal.pone.0145633.
   PubMed Web of Science ®Google Scholar
• Hayes JM, Wormald MR, Rudd PM, Davey GP. Fc gamma receptors: glycobiology and therapeutic prospects. J Inflamm Res. 2016;9:209–19. doi:10.2147/JIR.S121233.
   PubMed Web of Science ®Google Scholar
• Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293(5532):1155–59. doi:10.1126/science.1061692.
   PubMed Web of Science ®Google Scholar
• Johnson PM, Michaelsen TE, Scopes PM. Conformation of the hinge region and various fragments of human IgG3. Scand J Immunol. 1975;4(2):113–19. doi:10.1111/j.1365-3083.1975.tb02607.x.
   PubMed Web of Science ®Google Scholar
• Shakib F. The Human IgG subclasses: molecular analysis of structure, function, and regulation. 1st ed. Oxford: New York, USA: Pergamon Press. 1990. 316. xi
   Google Scholar
• Roux KH, Strelets L, Brekke OH, Sandlie I, Michaelsen TE. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. Journal of Immunology. 1998;161:4083–90.
   PubMed Web of Science ®Google Scholar
• Ryazantsev S, Tishchenko V, Vasiliev V, Zav’yalov V, Abramov V. Structure of human myeloma IgG3 Kuc. European Journal of Biochemistry. 1990;190(2):393–99. doi:10.1111/j.1432-1033.1990.tb15588.x.
   PubMedGoogle Scholar
• Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. Journal of Immunology. 1997;159:3372–82.
   PubMed Web of Science ®Google Scholar
• Cavacini LA, Emes CL, Power J, Desharnais FD, Duval M, Montefiori D, et al. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. Journal of Immunology. 1995;155:3638–44.
   PubMed Web of Science ®Google Scholar
• Wang P, Yang X. Neutralization Efficiency Is Greatly Enhanced by Bivalent Binding of an Antibody to Epitopes in the V4 Region and the Membrane-Proximal External Region within One Trimer of Human Immunodeficiency Virus Type 1 Glycoproteins. J Virol. 2010;84(14):7114–23. doi:10.1128/JVI.00545-10.
   PubMed Web of Science ®Google Scholar
• Dimmock NJ, Hardy SA. Valency of antibody binding to virions and its determination by surface plasmon resonance. Rev Med Virol. 2004;14(2):123–35. doi:10.1002/rmv.419.
   PubMed Web of Science ®Google Scholar
• Scharf O, Golding H, King LR, Eller N, Frazier D, Golding B, et al Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol. 2001;75(14):6558–65. doi:10.1128/JVI.75.14.6558-6565.2001.
   PubMed Web of Science ®Google Scholar
• Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. Characterization of Molecular Features, Antigen-Binding, and in Vitro Properties of IgG and IgM Variants of 4E10, an Anti-HIV Type 1 Neutralizing Monoclonal Antibody. AIDS Res Hum Retroviruses. 2004;20(7):755–62. doi:10.1089/0889222041524571.
   PubMed Web of Science ®Google Scholar
• Kunert R, Steinfellner W, Purtscher M, Assadian A, Katinger H. Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. Biotechnol Bioeng. 2000;67(1):97–103. doi:10.1002/(SICI)1097-0290(20000105)67:1<97::AID-BIT11>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Cavacini LA, Kuhrt D, Duval M, Mayer K, Posner MR. Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. AIDS Res Hum Retroviruses. 2003;19(9):785–92. doi:10.1089/088922203769232584.
   PubMed Web of Science ®Google Scholar
• Miranda LR, Duval M, Doherty H, Seaman MS, Posner MR, Cavacini LA. The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain. The Journal of Immunology. 2007;178(11):7132–38. doi:10.4049/jimmunol.178.11.7132.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell. 2016;165(7):1609–20. doi:10.1016/j.cell.2016.04.050.
   PubMed Web of Science ®Google Scholar
• Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, Garrett N, et al. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 2019;15(12):e1008064. doi:10.1371/journal.ppat.1008064.
   PubMed Web of Science ®Google Scholar
• Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell. 2015;160(3):433–46. doi:10.1016/j.cell.2015.01.016.
   PubMed Web of Science ®Google Scholar
• de Lange GG. Polymorphisms of human immunoglobulins: gm, Am, Em and Km allotypes. Exp Clin Immunogenet. 1989;6:7–17.
   PubMedGoogle Scholar
• Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, Garrett N, et al. Unveiling the Diversity of Immunoglobulin Heavy Constant Gamma (IGHG) Gene Segments in Brazilian Populations Reveals 28 Novel Alleles and Evidence of Gene Conversion and Natural Selection. Front Immunol. 2019;10:1161. doi:10.3389/fimmu.2019.01161.
   PubMed Web of Science ®Google Scholar
• Lefranc M-P, Lefranc G. Human Gm, Km, and Am Allotypes and Their Molecular Characterization: A Remarkable Demonstration of Polymorphism. In: Christiansen FT, Tait BD, editors. Immunogenetics: methods and Applications in Clinical Practice. Totowa: NJ, USA: Humana Press; 2012. p. 635–80.
   Google Scholar
• Huck S, Lefranc G, Lefranc MP. A human immunoglobulin IGHG3 allele (Gmb0,b1,c3,c5,u) with an IGHG4 converted region and three hinge exons. Immunogenetics. 1989;30(4):250–57. doi:10.1007/BF02421328.
   PubMed Web of Science ®Google Scholar
• Dard P, Huck S, Frippiat J-P, Lefranc G, Langaney A, Lefranc M-P, et al. The IGHG3 gene shows a structural polymorphism characterized by different hinge lengths: sequence of a new 2-exon hinge gene. Hum Genet. 1996;99(1):138–41. doi:10.1007/s004390050328.
   Web of Science ®Google Scholar
• Dard P, Lefranc M-P, Osipova L, Sanchez-Mazas A. DNA sequence variability of IGHG3 alleles associated to the main G3m haplotypes in human populations. European Journal of Human Genetics. 2001;9(10):765. doi:10.1038/sj.ejhg.5200700.
   PubMed Web of Science ®Google Scholar
• Dugoujon JM, Cambon-Thomsen A. Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Autoimmunity. 1995;22(4):245–60. doi:10.3109/08916939508995322.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Boies E, Squires J, Pandey JP, Suarez B, Oldfather J, et al. Interactive effect of genes associated with immunoglobulin allotypes and HLA specificities on susceptibility to Haemophilus influenzae disease. J Immunogenet. 1984;11(3–4):181–88. doi:10.1111/j.1744-313X.1984.tb01055.x.
   PubMedGoogle Scholar
• Ilic V, Milosevic-Jovcic N, Markovic D, Petrovic S, Stefanovic G. A biased Gm haplotype and Gm paraprotein allotype in multiple myeloma suggests a role for the Gm system in myeloma development. Int J Immunogenet. 2007;34(2):119–25. doi:10.1111/j.1744-313X.2007.00673.x.
   PubMed Web of Science ®Google Scholar
• Kagnoff MF, Weiss JB, Brown RJ, Lee T, Schanfield MS. Immunoglobulin allotype markers in gluten-sensitive enteropathy. Lancet. 1983;1(8331):952–53. doi:10.1016/S0140-6736(83)92080-9.
   PubMed Web of Science ®Google Scholar
• Nakao Y, Matsumoto H, Miyazaki T, Watanabe S, Mukojima T, Kawashima R, et al. Immunoglobulin G heavy-chain allotypes as possible genetic markers for human cancer. J Natl Cancer Inst. 1981;67(1):47–50.
   PubMedGoogle Scholar
• Pandey JP, Astemborski J, Thomas DL. Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus. J Virol. 2004;78(9):4561–65. doi:10.1128/JVI.78.9.4561-4565.2004.
   PubMed Web of Science ®Google Scholar
• Pandey JP, Goust JM, Salier JP, Fudenberg HH. Immunoglobulin G heavy chain (Gm) allotypes in multiple sclerosis. J Clin Invest. 1981;67(6):1797–800. doi:10.1172/JCI110220.
   PubMed Web of Science ®Google Scholar
• Grubb R, Hallberg T, Hammarstrom L, Oxelius VA, Smith CI, Soderstrom R, et al. Correlation between deficiency of immunoglobulin subclass G3 and Gm allotype. Acta Pathol Microbiol Immunol Scand C. 1986;94(5):187–91. doi:10.1111/j.1699-0463.1986.tb02110.x.
   PubMedGoogle Scholar
• Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2(1):599. doi:10.1038/ncomms1608.
   PubMed Web of Science ®Google Scholar
• Dechavanne C, Dechavanne S, Sadissou I, Lokossou AG, Alvarado F, Dambrun M, et al. Associations between an IgG3 polymorphism in the binding domain for FcRn, transplacental transfer of malaria-specific IgG3, and protection against Plasmodium falciparum malaria during infancy: A birth cohort study in Benin. PLoS Med. 2017;14(10):e1002403. doi:10.1371/journal.pmed.1002403.
   PubMed Web of Science ®Google Scholar
• Rispens T, Davies AM, Ooijevaar-de Heer P, Absalah S, Bende O, Sutton BJ, et al. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem. 2014;289(9):6098–109. doi:10.1074/jbc.M113.541813.
   PubMed Web of Science ®Google Scholar
• Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 2008;68(10):3863–72. doi:10.1158/0008-5472.CAN-07-6297.
   PubMed Web of Science ®Google Scholar
• Michaelsen TE, Aase A, Westby C, Sandlie I. Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scand J Immunol. 1990;32(5):517–28. doi:10.1111/j.1365-3083.1990.tb03192.x.
   PubMed Web of Science ®Google Scholar
• Sandlie I, Aase A, Westby C, Michaelsen TE. C1q binding to chimeric monoclonal IgG3 antibodies consisting of mouse variable regions and human constant regions with shortened hinge containing 15 to 47 amino acids. Eur J Immunol. 1989;19(9):1599–603. doi:10.1002/eji.1830190912.
   PubMed Web of Science ®Google Scholar
• Chu TH, Crowley AR, Backes I, Chang C, Tay M, Broge T, et al.  Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. PLoS Pathog. 2020;16(2):e1008083. doi:10.1371/journal.ppat.1008083.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins. Annu Rev Immunol. 2007;25(1):21–50. doi:10.1146/annurev.immunol.25.022106.141702.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, et al. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. Front Immunol. 2017;8:877. doi:10.3389/fimmu.2017.00877.
   PubMed Web of Science ®Google Scholar
• Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods. 2005;306(1–2):151–60. doi:10.1016/j.jim.2005.08.009.
   PubMed Web of Science ®Google Scholar
• Sonneveld ME, Koeleman CAM, Plomp HR, Wuhrer M, van der Schoot CE, Vidarsson G. Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies. Front Immunol. 2018;9:129. doi:10.3389/fimmu.2018.00129.
   PubMed Web of Science ®Google Scholar
• Vestrheim AC, Moen A, Egge-Jacobsen W, Bratlie DB, Michaelsen TE. Different glycosylation pattern of human IgG1 and IgG3 antibodies isolated from transiently as well as permanently transfected cell lines. Scand J Immunol. 2013;77(5):419–28. doi:10.1111/sji.12046.
   PubMed Web of Science ®Google Scholar
• Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcalpha receptor interactions. J Biol Chem. 1998;273(4):2260–72. doi:10.1074/jbc.273.4.2260.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Tetaert D, Debuire B, Lin LC, Putnam FW. Complete amino acid sequence of the delta heavy chain of human immunoglobulin D. Proc Natl Acad Sci U S A. 1982;79(9):2850–54. doi:10.1073/pnas.79.9.2850.
   PubMed Web of Science ®Google Scholar
• Plomp R, Dekkers G, Rombouts Y, Visser R, Koeleman CA, Kammeijer GS, et al. Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). Molecular & Cellular Proteomics: MCP. 2015;14(5):1373–84. doi:10.1074/mcp.M114.047381.
   PubMed Web of Science ®Google Scholar
• Kim H, Yamaguchi Y, Masuda K, et al. O-glycosylation in hinge region of mouse immunoglobulin G2b. J Biol Chem. 1994;269(16):12345–50. doi:10.1016/S0021-9258(17)32722-9.
   PubMed Web of Science ®Google Scholar
• Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol. 1981;11(12):1012–16. doi:10.1002/eji.1830111212.
   PubMed Web of Science ®Google Scholar
• Klaus GG, Pepys MB, Kitajima K, Askonas BA. Activation of mouse complement by different classes of mouse antibody. Immunology. 1979;38:687–95.
   PubMed Web of Science ®Google Scholar
• Michaelsen TE, Kolberg J, Aase A, Herstad TK, Hoiby EA. The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis. Scand J Immunol. 2004;59(1):34–39. doi:10.1111/j.0300-9475.2004.01362.x.
   PubMed Web of Science ®Google Scholar
• Yuan R, Clynes R, Oh J, Ravetch JV, Scharff MD. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses. J Exp Med. 1998;187(4):641–48. doi:10.1084/jem.187.4.641.
   PubMed Web of Science ®Google Scholar
• Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology. 2004;111(1):66–74. doi:10.1111/j.1365-2567.2004.01767.x.
   PubMed Web of Science ®Google Scholar
• Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F, et al. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. Journal of Immunology. 2012;188(9):4405–11. doi:10.4049/jimmunol.1200090.
   PubMed Web of Science ®Google Scholar
• Attanasio R, Jayashankar L, Engleman CN, Scinicariello F. Baboon immunoglobulin constant region heavy chains: identification of four IGHG genes. Immunogenetics. 2002;54(8):556–61. doi:10.1007/s00251-002-0505-1.
   PubMed Web of Science ®Google Scholar
• Giudicelli V, Duroux P, Ginestoux C, Folch G, Jabado-Michaloud J, Chaume D, et al. IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Res. 2006;34(90001):D781–784. doi:10.1093/nar/gkj088.
   PubMedGoogle Scholar
• Tillib SV, Vyatchanin AS, Muyldermans S. Molecular analysis of heavy chain-only antibodies of Camelus bactrianus. Biochemistry (Mosc). 2014;79(12):1382–90. doi:10.1134/S000629791412013X.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–48. doi:10.1038/363446a0.
   PubMed Web of Science ®Google Scholar
• Daley LP, Kutzler MA, Bennett BW, Smith MC, Glaser AL, Appleton JA. Effector functions of camelid heavy-chain antibodies in immunity to West Nile virus. Clinical and Vaccine Immunology: CVI. 2010;17(2):239–46. doi:10.1128/CVI.00421-09.
   PubMedGoogle Scholar
• Ramesh A, Darko S, Hua A, Overman G, Ransier A, Francica JR, et al. Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies. Front Immunol. 2017;8:1407. doi:10.3389/fimmu.2017.01407.
   PubMed Web of Science ®Google Scholar
• Lefranc MP. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 2001;29(1):207–09. doi:10.1093/nar/29.1.207.
   PubMed Web of Science ®Google Scholar
• D’Addabbo P, Scascitelli M, Giambra V, Rocchi M, Frezza D. Position and sequence conservation in Amniota of polymorphic enhancer HS1.2 within the palindrome of IgH 3ʹRegulatory Region. BMC Evol Biol. 2011;11(1):71. doi:10.1186/1471-2148-11-71.
   PubMedGoogle Scholar
• Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. 2008;26(1):261–92. doi:10.1146/annurev.immunol.26.021607.090248.
   PubMedGoogle Scholar
• Valenzuela NM, Schaub S. The Biology of IgG Subclasses and Their Clinical Relevance to Transplantation. Transplantation. 2018;102:S7–S13. doi:10.1097/TP.0000000000001816.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD. Isotype switching by human B cells is division-associated and regulated by cytokines. Journal of Immunology. 2002;169(8):4298–306. doi:10.4049/jimmunol.169.8.4298.
   PubMed Web of Science ®Google Scholar
• Santana SS, Silva DA, Vaz LD, Pirovani CP, Barros GB, Lemos EM, et al. Analysis of IgG subclasses (IgG1 and IgG3) to recombinant SAG2A protein from Toxoplasma gondii in sequential serum samples from patients with toxoplasmosis. Immunol Lett. 2012;143(2):193–201. doi:10.1016/j.imlet.2012.02.008.
   PubMed Web of Science ®Google Scholar
• Yates NL, Lucas JT, Nolen TL, Vandergrift NA, Soderberg KA, Seaton KE, et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS (London, England). 2011;25(17):2089–97. doi:10.1097/QAD.0b013e32834b348e.
   PubMed Web of Science ®Google Scholar
• Dugast A-S, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, et al. Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol. 2014;44(10):2925–37. doi:10.1002/eji.201344305.
   PubMed Web of Science ®Google Scholar
• Hussain R, Kifayet A, Chiang TJ. Immunoglobulin G1 (IgG1) and IgG3 antibodies are markers of progressive disease in leprosy. Infect Immun. 1995;63(2):410–15. doi:10.1128/IAI.63.2.410-415.1995.
   PubMed Web of Science ®Google Scholar
• Hussain R, Dawood G, Abrar N, Toossi Z, Minai A, Dojki M, et al. Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients. Clin Diagn Lab Immunol. 1995;2(6):726–32. doi:10.1128/CDLI.2.6.726-732.1995.
   PubMedGoogle Scholar
• Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014;6(228):228ra238. doi:10.1126/scitranslmed.3007736.
   Web of Science ®Google Scholar
• Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6(228):228ra239. doi:10.1126/scitranslmed.3007730.
   Web of Science ®Google Scholar
• Karnasuta C, Akapirat S, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, et al. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. AIDS Res Hum Retroviruses. 2017;33(5):410–23. doi:10.1089/aid.2016.0204.
   PubMed Web of Science ®Google Scholar
• Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, et al. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J Immunol Methods. 2017;443:33–44. doi:10.1016/j.jim.2017.01.010.
   PubMed Web of Science ®Google Scholar
• Jackson KJ, Wang Y, Collins AM. Human immunoglobulin classes and subclasses show variability in VDJ gene mutation levels. Immunol Cell Biol. 2014;92(8):729–33. doi:10.1038/icb.2014.44.
   PubMed Web of Science ®Google Scholar
• Collins AM, Jackson KJ. A Temporal Model of Human IgE and IgG Antibody Function. Front Immunol. 2013;4:235. doi:10.3389/fimmu.2013.00235.
   PubMed Web of Science ®Google Scholar
• van Zelm MC. B cells take their time: sequential IgG class switching over the course of an immune response? Immunol Cell Biol. 2014;92(8):645–46. doi:10.1038/icb.2014.48.
   PubMed Web of Science ®Google Scholar
• Kitaura K, Yamashita H, Ayabe H, Shini T, Matsutani T, Suzuki R. Different Somatic Hypermutation Levels among Antibody Subclasses Disclosed by a New Next-Generation Sequencing-Based Antibody Repertoire Analysis. Front Immunol. 2017;8:389. doi:10.3389/fimmu.2017.00389.
   PubMed Web of Science ®Google Scholar
• Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood. 2011;118(8):2150–58. doi:10.1182/blood-2011-04-345579.
   PubMed Web of Science ®Google Scholar
• Horns F, Vollmers C, Croote D, Mackey SF, Swan GE, Dekker CL, et al. Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching. Elife. 2016;5.
   Web of Science ®Google Scholar
• Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med. 1994;179(2):757–62. doi:10.1084/jem.179.2.757.
   PubMed Web of Science ®Google Scholar
• Fujieda S, Zhang K, Saxon A. IL-4 plus CD40 monoclonal antibody induces human B cells gamma subclass-specific isotype switch: switching to gamma 1, gamma 3, and gamma 4, but not gamma 2. Journal of Immunology. 1995;155:2318–28.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ding Z, Heyman B. IgG3-antigen complexes are deposited on follicular dendritic cells in the presence of C1q and C3. Sci Rep. 2017;7(1):5400. doi:10.1038/s41598-017-05704-3.
   PubMedGoogle Scholar
• Zhang L, Ding Z, Xu H, Heyman B. Marginal zone B cells transport IgG3-immune complexes to splenic follicles. Journal of Immunology. 2014;193(4):1681–89. doi:10.4049/jimmunol.1400331.
   PubMed Web of Science ®Google Scholar
• Butler NR, Barr M, Glenny AT. Immunization of young babies against diphtheria. Br Med J. 1954;1(4860):476–81. doi:10.1136/bmj.1.4860.476.
   PubMedGoogle Scholar
• Osborn JJ, Dancis J, Julia JF. Studies of the immunology of the newborn infant. II. Interference with active immunization by passive transplacental circulating antibody. Pediatrics. 1952;10:328–34.
   PubMed Web of Science ®Google Scholar
• Terry WD, Matthews BW, Davies DR. Crystallographic studies of a human immunoglobulin. Nature. 1968;220(5164):239–41. doi:10.1038/220239a0.
   PubMed Web of Science ®Google Scholar
• Lai JI, Licht AF, Dugast AS, Suscovich T, Choi I, Bailey-Kellogg C, et al. Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J Virol. 2014;88(5):2799–809. doi:10.1128/JVI.03130-13.
   PubMed Web of Science ®Google Scholar
• Hjelholt A, Christiansen G, Sorensen US, Birkelund S. IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog Dis. 2013;67(3):206–13. doi:10.1111/2049-632X.12034.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Liu P, Williams LD, McRaven MD, Sawant S, Gurley TC, et al. Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathog. 2016;12(8):e1005817. doi:10.1371/journal.ppat.1005817.
   PubMed Web of Science ®Google Scholar
• Musich T, Li L, Liu L, Zolla-Pazner S, Robert-Guroff M, Gorny MK. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner. J Virol. 2017;91(8). doi:10.1128/JVI.02325-16.
   PubMedGoogle Scholar
• Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, et al. Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcgamma Receptor Profile. Journal of Immunology. 2017;199(1):204–11. doi:10.4049/jimmunol.1700116.
   PubMed Web of Science ®Google Scholar
• Rosner T, Lohse S, Peipp M, Valerius T, Derer S. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop. Journal of Immunology. 2014;193(3):1485–95. doi:10.4049/jimmunol.1400329.
   PubMed Web of Science ®Google Scholar
• Rosner T, Derer S, Kellner C, Dechant M, Lohse S, Vidarsson G, et al. An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. Br J Haematol. 2013;161(2):282–86. doi:10.1111/bjh.12209.
   PubMed Web of Science ®Google Scholar
• Giuntini S, Granoff DM, Beernink PT, Ihle O, Bratlie D, Michaelsen TE. Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity. Clinical and Vaccine Immunology: CVI. 2016;23(8):698–706. doi:10.1128/CVI.00193-16.
   PubMedGoogle Scholar
• Kim JH, Park S, Hwang YI, Jang SH, Jung KS, Sim YS, et al. Immunoglobulin G Subclass Deficiencies in Adult Patients with Chronic Airway Diseases. J Korean Med Sci. 2016;31(10):1560–65. doi:10.3346/jkms.2016.31.10.1560.
   PubMed Web of Science ®Google Scholar
• Barton JC, Bertoli LF, Barton JC, Acton RT. Selective subnormal IgG3 in 121 adult index patients with frequent or severe bacterial respiratory tract infections. Cell Immunol. 2016;299:50–57. doi:10.1016/j.cellimm.2015.09.004.
   PubMed Web of Science ®Google Scholar
• Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol. 2010;159(3):344–50. doi:10.1111/j.1365-2249.2009.04062.x.
   PubMed Web of Science ®Google Scholar
• Veskitkul J, Vichyanond P, Pacharn P, Visitsunthorn N, Jirapongsananuruk O. Clinical characteristics of recurrent acute rhinosinusitis in children. Asian Pacific Journal of Allergy and Immunology. 2015;33(4):276–80. doi:10.12932/AP0591.33.4.2015.
   PubMed Web of Science ®Google Scholar
• Herrod HG. Follow-up of pediatric patients with recurrent infection and mild serologic immune abnormalities. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology. 1997;79(5):460–64. doi:10.1016/S1081-1206(10)63044-X.
   PubMed Web of Science ®Google Scholar
• Bernatowska-Matuszkiewicz E, Pac M, Skopcynska H, Pum M, Eibl MM. Clinical efficacy of intravenous immunoglobulin in patients with severe inflammatory chest disease and IgG3 subclass deficiency. Clin Exp Immunol. 1991;85(2):193–97. doi:10.1111/j.1365-2249.1991.tb05703.x.
   PubMed Web of Science ®Google Scholar
• Olinder-Nielsen AM, Granert C, Forsberg P, Friman V, Vietorisz A, Bjorkander J. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis. 2007;39(1):44–50. doi:10.1080/00365540600951192.
   PubMed Web of Science ®Google Scholar
• Barlan IB, Geha RS, Schneider LC. Therapy for patients with recurrent infections and low serum IgG3 levels. J Allergy Clin Immunol. 1993;92(2):353–55. doi:10.1016/0091-6749(93)90179-J.
   PubMed Web of Science ®Google Scholar
• Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. J Clin Invest. 2019;129(11):4838–49. doi:10.1172/JCI126391.
   PubMed Web of Science ®Google Scholar
• Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis. 2012;205(7):1147–54. doi:10.1093/infdis/jis033.
   PubMed Web of Science ®Google Scholar
• Walker MR, Eltahla AA, Mina MM, Li H, Lloyd AR, Bull RA. Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection. Viruses. 2020;12(1). doi:10.3390/v12010075.
   Google Scholar
• Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg. 1998;58(4):406–13. doi:10.4269/ajtmh.1998.58.406.
   PubMed Web of Science ®Google Scholar
• Metzger WG, Okenu DMN, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, McBride JS, Greenwood BM, Conway DJ. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol. 2003;25(6):307–12. doi:10.1046/j.1365-3024.2003.00636.x.
   PubMed Web of Science ®Google Scholar
• Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape J-F, et al. Long-Term Clinical Protection from Falciparum Malaria Is Strongly Associated with IgG3 Antibodies to Merozoite Surface Protein 3. PLoS Med. 2007;4(11):e320. doi:10.1371/journal.pmed.0040320.
   PubMed Web of Science ®Google Scholar
• Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun. 2009;77(3):1165–74. doi:10.1128/IAI.01129-08.
   PubMed Web of Science ®Google Scholar
• Lang PO, Mendes A, Socquet J, Assir N, Govind S, Aspinall R. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012;7:55–64. doi:10.2147/CIA.S25215.
   PubMed Web of Science ®Google Scholar
• Stepanova L, Naykhin A, Kolmskog C, Jonson G, Barantceva I, Bichurina M, et al. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology. 2002;24(3):193–201. doi:10.1016/S1386-6532(01)00246-3.
   PubMed Web of Science ®Google Scholar
• Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Blomberg BB. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season. Immunity & Ageing: I & A. 2013;10(1):14. doi:10.1186/1742-4933-10-14.
   PubMedGoogle Scholar
• El-Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis. 1999;180(4):1356–60. doi:10.1086/315003.
   PubMed Web of Science ®Google Scholar
• Cao RY, Dong DY, Liu RJ, Han JF, Wang GC, Zhao H, et al. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One. 2013;8(5):e64024. doi:10.1371/journal.pone.0064024.
   PubMedGoogle Scholar
• Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, et al. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Rep. 2018;24(7):1802–1815 e1805. doi:10.1016/j.celrep.2018.07.035.
   PubMed Web of Science ®Google Scholar
• Zimmerman MG, Quicke KM, O'Neal JT, Arora N, Machiah D, Priyamvada L, et al. Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. Cell Host Microbe. 2018;24(5):731–742 e736. doi:10.1016/j.chom.2018.10.008.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Gresh L, Halloran ME, et al.Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–32. doi:10.1126/science.aan6836.
   PubMed Web of Science ®Google Scholar
• Thulin NK, Brewer RC, Sherwood R, Bournazos S, Edwards KG, Ramadoss NS, et al. Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants. Cell Rep. 2020;31(6):107642. doi:10.1016/j.celrep.2020.107642.
   PubMed Web of Science ®Google Scholar
• Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, et al. IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science. 2017;355(6323):395–98. doi:10.1126/science.aai8128.
   PubMed Web of Science ®Google Scholar
• Liu F, Bergami PL, Duval M, Kuhrt D, Posner M, Cavacini L. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res Hum Retroviruses. 2003;19(7):597–607. doi:10.1089/088922203322230969.
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6(5):343–57. doi:10.1038/nri1837.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther. 2007;7(9):1401–13. doi:10.1517/14712598.7.9.1401.
   PubMed Web of Science ®Google Scholar
• Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol. 2007;25(12):1369–72. doi:10.1038/nbt1207-1369.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8(3):226–34. doi:10.1038/nrd2804.
   PubMed Web of Science ®Google Scholar
• Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49(4):673–80. doi:10.1172/JCI106279.
   PubMed Web of Science ®Google Scholar
• Kronvall G, Williams RC Jr. Differences in anti-protein A activity among IgG subgroups. Journal of Immunology. 1969;103:828–33.
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018;15(1):e1002493. doi:10.1371/journal.pmed.1002493.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53. doi:10.1128/AAC.01285-13.
   PubMed Web of Science ®Google Scholar
• Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388). doi:10.1126/scitranslmed.aaj1928.
   Google Scholar
• Webster CI, Bryson CJ, Cloake EA, Jones TD, Austin MJ, Karle AC, et al. A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors. MAbs. 2016;8(2):253–63. doi:10.1080/19420862.2015.1128605.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, de Groot E, Nurmohamed MT, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 2010;12(6):R221. doi:10.1186/ar3208.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics. 2009;19(5):383–87. doi:10.1097/FPC.0b013e32832a06bf.
   PubMed Web of Science ®Google Scholar
• Shearer MH, Dark RD, Chodosh J, Kennedy RC. Comparison and Characterization of Immunoglobulin G Subclasses among Primate Species. Clinical Diagnostic Laboratory Immunology. 1999;6(6):953–58. doi:10.1128/CDLI.6.6.953-958.1999.
   PubMedGoogle Scholar
• Van Loghem E, Frangione B, Recht B, Franklin EC. Staphylococcal protein A and human IgG subclasses and allotypes. Scand J Immunol. 1982;15(3):275–78. doi:10.1111/j.1365-3083.1982.tb00649.x.
   PubMed Web of Science ®Google Scholar
• Lopez E, Scott NE, Wines BD, Hogarth PM, Wheatley AK, Kent SJ, et al. Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind Fcγ Receptors: implications for Measuring Fc Dependent Antibody Functions. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.02415
   Google Scholar
• Saito S, Namisaki H, Hiraishi K, Takahashi N, Iida S. A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress. Protein Science: A Publication of the Protein Society. 2019;28(5):900–09. doi:10.1002/pro.3598.
   PubMed Web of Science ®Google Scholar
• Ito T, Tsumoto K. Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress. Protein Science: A Publication of the Protein Society. 2013;22(11):1542–51. doi:10.1002/pro.2340.
   PubMed Web of Science ®Google Scholar
• Baici A, Knopfel M, Fehr K, Skvaril F, Boni A. Kinetics of the different susceptibilities of the four human immunoglobulin G subclasses to proteolysis by human lysosomal elastase. Scand J Immunol. 1980;12(1):41–50. doi:10.1111/j.1365-3083.1980.tb00039.x.
   PubMed Web of Science ®Google Scholar
• Turner MW, Bennich HH, Natvig JB. Simple method of subtyping human G-myeloma proteins based on sensitivity to pepsin digestion. Nature. 1970;225(5235):853–55. doi:10.1038/225853b0.
   PubMedGoogle Scholar
• Virella G, Parkhouse RM. Papain sensitivity of heavy chain sub-classes in normal human IgG and localizaton of antigenic determinants for the sub-classes. Immunochemistry. 1971;8(3):243–50. doi:10.1016/0019-2791(71)90478-2.
   PubMedGoogle Scholar
• Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol. 2005;23(5):584–90. doi:10.1038/nbt1087.
   PubMed Web of Science ®Google Scholar
• Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002;8(4):343–48. doi:10.1038/nm0402-343.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Shapiro MB, Powell R, Malherbe DC, McBurney SP, Pandey S, et al. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. J Virol. 2018;92(11). doi:10.1128/JVI.02198-17.
   Google Scholar
• Braster R, Grewal S, Visser R, Einarsdottir HK, van Egmond M, Vidarsson G, et al. Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice. PLoS One. 2017;12(5):e0177736. doi:10.1371/journal.pone.0177736.
   PubMed Web of Science ®Google Scholar
• Giuntini S, Reason DC, Granoff DM, Weiser JN. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun. 2012;80(1):187–94. doi:10.1128/IAI.05956-11.
   PubMed Web of Science ®Google Scholar
• Lucisano Valim YM, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol. 1991;84(1):1–8. doi:10.1111/j.1365-2249.1991.tb08115.x.
   PubMed Web of Science ®Google Scholar
• Varshney AK, Kuzmicheva GA, Lin J, Sunley KM, Bowling RA, Jr., Kwan TY, et al. A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018;13(1):e0190537. doi:10.1371/journal.pone.0190537.
   PubMed Web of Science ®Google Scholar
• Huynh T, Stecher M, Mckinnon J, Jung N, Rupp ME. Safety and Tolerability of 514G3, a True Human Anti-Protein A Monoclonal Antibody for the Treatment of S. aureus Bacteremia. Open Forum Infectious Diseases. 2016;3(suppl_1). doi:10.1093/ofid/ofw172.1057.
   Google Scholar
• Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr. Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. Cancer Immunology Research. 2015;3(12):1325–32. doi:10.1158/2326-6066.CIR-15-0122.
   PubMed Web of Science ®Google Scholar
• Natsume A, Shimizu-Yokoyama Y, Satoh M, Shitara K, Niwa R. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 2009;100(12):2411–18. doi:10.1111/j.1349-7006.2009.01327.x.
   PubMed Web of Science ®Google Scholar
• Alsaid H, Skedzielewski T, Rambo MV, Hunsinger K, Hoang B, Fieles W, et al. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. PLoS One. 2017;12(4):e0176075. doi:10.1371/journal.pone.0176075.
   PubMed Web of Science ®Google Scholar
• Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, et al. Immuno-PET Imaging to Assess Target Engagement: experience from8 Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. J Nucl Med. 2019;60(7):902–09. doi:10.2967/jnumed.118.214726.
   PubMed Web of Science ®Google Scholar
• Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, et al. Response to ERBB3-Directed Targeted Therapy in NRGRearranged Cancers. Cancer Discov. 2018;8(6):686–95. doi:10.1158/2159-8290.CD-17-1004.
   PubMed Web of Science ®Google Scholar
• Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, et al. Engineered antibodies with increased activity to recruit complement. Journal of Immunology. 2001;166(4):2571–75. doi:10.4049/jimmunol.166.4.2571.
   PubMed Web of Science ®Google Scholar
• Kellner C, Derer S, Valerius T, Boosting PM. ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods. 2014;65(1):105–13. doi:10.1016/j.ymeth.2013.06.036.
   PubMed Web of Science ®Google Scholar
• Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs. 2010;2(2):181–89. doi:10.4161/mabs.2.2.11158.
   PubMed Web of Science ®Google Scholar
• Klein JS, Jiang S, Galimidi RP, Keeffe JR, Bjorkman PJ. Design and characterization of structured protein linkers with differing flexibilities. Protein Engineering, Design & Selection: PEDS. 2014;27(10):325–30. doi:10.1093/protein/gzu043.
   PubMed Web of Science ®Google Scholar